SCN1A and Dravet syndrome: Treatment with phytocannabinoids, such as CBCA and CBCVA [156] CBGA, CBDVA, and CBGA [157], as well as the cannabinoid-like compound magnolol from non-cannabis plant Magnolia officinalis [158], reduced spontaneous seizures and improved survival in the Scn1a+/− mouse model of DS.